Cargando…
Cardiovascular Safety of Hydroxychloroquine–Azithromycin in 424 COVID-19 Patients
Background and Objectives: Hydroxychloroquine (HCQ) combined with azithromycin (AZM) has been widely administered to patients with COVID-19 despite scientific controversies. In particular, the potential of prolong cardiac repolarization when using this combination has been discussed. Materials and M...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10220868/ https://www.ncbi.nlm.nih.gov/pubmed/37241095 http://dx.doi.org/10.3390/medicina59050863 |
_version_ | 1785049320410578944 |
---|---|
author | Million, Matthieu Lagier, Jean-Christophe Hourdain, Jérôme Franceschi, Frédéric Deharo, Jean-Claude Parola, Philippe Brouqui, Philippe |
author_facet | Million, Matthieu Lagier, Jean-Christophe Hourdain, Jérôme Franceschi, Frédéric Deharo, Jean-Claude Parola, Philippe Brouqui, Philippe |
author_sort | Million, Matthieu |
collection | PubMed |
description | Background and Objectives: Hydroxychloroquine (HCQ) combined with azithromycin (AZM) has been widely administered to patients with COVID-19 despite scientific controversies. In particular, the potential of prolong cardiac repolarization when using this combination has been discussed. Materials and Methods: We report a pragmatic and simple safety approach which we implemented among the first patients treated for COVID-19 in our center in early 2020. Treatment contraindications were the presence of severe structural or electrical heart disease, baseline corrected QT interval (QTc) > 500 ms, hypokalemia, or other drugs prolonging QTc that could not be interrupted. Electrocardiogram and QTc was evaluated at admission and re-evaluated after 48 h of the initial prescription. Results: Among the 424 consecutive adult patients (mean age 46.3 ± 16.1 years; 216 women), 21.5% patients were followed in conventional wards and 78.5% in a day-care unit. A total of 11 patients (2.6%) had contraindications to the HCQ-AZ combination. In the remaining 413 treated patients, there were no arrhythmic events in any patient during the 10-day treatment regimen. QTc was slightly but statistically significantly prolonged by 3.75 ± 25.4 ms after 2 days of treatment (p = 0.003). QTc prolongation was particularly observed in female outpatients <65 years old without cardiovascular disease. Ten patients (2.4%) developed QTc prolongation > 60 ms, and none had QTc > 500 ms. Conclusions: This report does not aim to contribute to knowledge of the efficacy of treating COVID-19 with HCQ-AZ. However, it shows that a simple initial assessment of patient medical history, electrocardiogram (ECG), and kalemia identifies contraindicated patients and enables the safe treatment of COVID-19 patients with HCQ-AZ. QT-prolonging anti-infective drugs can be used safely in acute life-threatening infections, provided that a strict protocol and close collaboration between infectious disease specialists and rhythmologists are applied. |
format | Online Article Text |
id | pubmed-10220868 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-102208682023-05-28 Cardiovascular Safety of Hydroxychloroquine–Azithromycin in 424 COVID-19 Patients Million, Matthieu Lagier, Jean-Christophe Hourdain, Jérôme Franceschi, Frédéric Deharo, Jean-Claude Parola, Philippe Brouqui, Philippe Medicina (Kaunas) Article Background and Objectives: Hydroxychloroquine (HCQ) combined with azithromycin (AZM) has been widely administered to patients with COVID-19 despite scientific controversies. In particular, the potential of prolong cardiac repolarization when using this combination has been discussed. Materials and Methods: We report a pragmatic and simple safety approach which we implemented among the first patients treated for COVID-19 in our center in early 2020. Treatment contraindications were the presence of severe structural or electrical heart disease, baseline corrected QT interval (QTc) > 500 ms, hypokalemia, or other drugs prolonging QTc that could not be interrupted. Electrocardiogram and QTc was evaluated at admission and re-evaluated after 48 h of the initial prescription. Results: Among the 424 consecutive adult patients (mean age 46.3 ± 16.1 years; 216 women), 21.5% patients were followed in conventional wards and 78.5% in a day-care unit. A total of 11 patients (2.6%) had contraindications to the HCQ-AZ combination. In the remaining 413 treated patients, there were no arrhythmic events in any patient during the 10-day treatment regimen. QTc was slightly but statistically significantly prolonged by 3.75 ± 25.4 ms after 2 days of treatment (p = 0.003). QTc prolongation was particularly observed in female outpatients <65 years old without cardiovascular disease. Ten patients (2.4%) developed QTc prolongation > 60 ms, and none had QTc > 500 ms. Conclusions: This report does not aim to contribute to knowledge of the efficacy of treating COVID-19 with HCQ-AZ. However, it shows that a simple initial assessment of patient medical history, electrocardiogram (ECG), and kalemia identifies contraindicated patients and enables the safe treatment of COVID-19 patients with HCQ-AZ. QT-prolonging anti-infective drugs can be used safely in acute life-threatening infections, provided that a strict protocol and close collaboration between infectious disease specialists and rhythmologists are applied. MDPI 2023-04-29 /pmc/articles/PMC10220868/ /pubmed/37241095 http://dx.doi.org/10.3390/medicina59050863 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Million, Matthieu Lagier, Jean-Christophe Hourdain, Jérôme Franceschi, Frédéric Deharo, Jean-Claude Parola, Philippe Brouqui, Philippe Cardiovascular Safety of Hydroxychloroquine–Azithromycin in 424 COVID-19 Patients |
title | Cardiovascular Safety of Hydroxychloroquine–Azithromycin in 424 COVID-19 Patients |
title_full | Cardiovascular Safety of Hydroxychloroquine–Azithromycin in 424 COVID-19 Patients |
title_fullStr | Cardiovascular Safety of Hydroxychloroquine–Azithromycin in 424 COVID-19 Patients |
title_full_unstemmed | Cardiovascular Safety of Hydroxychloroquine–Azithromycin in 424 COVID-19 Patients |
title_short | Cardiovascular Safety of Hydroxychloroquine–Azithromycin in 424 COVID-19 Patients |
title_sort | cardiovascular safety of hydroxychloroquine–azithromycin in 424 covid-19 patients |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10220868/ https://www.ncbi.nlm.nih.gov/pubmed/37241095 http://dx.doi.org/10.3390/medicina59050863 |
work_keys_str_mv | AT millionmatthieu cardiovascularsafetyofhydroxychloroquineazithromycinin424covid19patients AT lagierjeanchristophe cardiovascularsafetyofhydroxychloroquineazithromycinin424covid19patients AT hourdainjerome cardiovascularsafetyofhydroxychloroquineazithromycinin424covid19patients AT franceschifrederic cardiovascularsafetyofhydroxychloroquineazithromycinin424covid19patients AT deharojeanclaude cardiovascularsafetyofhydroxychloroquineazithromycinin424covid19patients AT parolaphilippe cardiovascularsafetyofhydroxychloroquineazithromycinin424covid19patients AT brouquiphilippe cardiovascularsafetyofhydroxychloroquineazithromycinin424covid19patients |